After the breakthrough of direct antiviral agents (DAA) for hepatitis C virus (HCV) treatment, a seminal study from the Barcelona Clinic Liver Cancer team suggested a potential increase of hepatocellular carcinoma (HCC) recurrence (“a note of caution”) after DAA implementation in HCV cirrhotic patients treated for HCC.1 This report was based on a retrospective analysis of 58 patients who exhibited a higher than expected rate of tumor recurrence after the combination of HCC treatment and DAA therapy.